The public record for Intersect ENT, Inc. centers on one premarket approval, P100044, and its supplements. The original approval, dated August 11, 2011, covers the Propel sinus implant; later supplements address labeling and manufacturing changes. The supplied filings list the applicant at a Menlo Park, California address, while the Summary of Safety and Effectiveness Data gives a Palo Alto address for the same applicant. Neither filing address is treated here as a verified headquarters. [1][3][8]
The approved device and its components
According to the Summary of Safety and Effectiveness Data, Propel is a bioabsorbable implant designed to maintain patency of the sinus cavity, separating mucosal tissues, stabilizing the middle turbinate, preventing obstruction by adhesions, and reducing edema. The labeling published by the National Library of Medicine describes the implant as manufactured from poly(L-lactide-co-glycolide) and containing mometasone furoate as the active ingredient, a synthetic corticosteroid with anti-inflammatory activity. [8][9]
The same labeling distinguishes three configurations: Propel and Propel Mini maintain patency of the sinus cavity, while Propel Contour maintains patency of the sinus ostium. An establishment registration and device listing record for product code OWO names Propel Contour Sinus Implant, Propel Mini Sinus Implant, Propel Mini Sinus Implant with Straight Deliver System (SDS), and Propel Sinus Implant under the classification name drug-eluting sinus. [7][9]
Original approval and stated contraindications
P100044 was approved on August 11, 2011, following a receipt date of December 6, 2010, with a Federal Register notice date of August 19, 2011. The approval order describes the device as indicated for patients 18 years of age and older following ethmoid sinus surgery to maintain patency, reducing the need for post-operative intervention such as surgical adhesion lysis or oral steroids. [3]
The Summary of Safety and Effectiveness Data lists contraindications for patients with suspected or confirmed intolerance to mometasone furoate and for patients with known hypersensitivity to lactide, glycolide, or caprolactone copolymers. It refers readers to the labeling for warnings and precautions rather than restating them. [8]
Recent supplement activity
Supplement S060, received June 26, 2026 and decided September 23, 2026, was approved as a real-time process supplement under the labeling change reason covering indications, instructions, shelf life, or tradename. Its approval order states a shelf-life extension of the Propel Family Products from 24 months to 36 months. [1]
Supplement S061, received August 24, 2026 and decided September 22, 2026, was handled as a 30-day notice for a process change involving manufacturer, sterilizer, packager, or supplier. Its approval order describes implementing an automated vision sensor to inspect correct or incorrect packaging orientation for the Propel Product Family when placed in a shipper. [2]
How to read the filing counts
The supplied collection contains three linked premarket approval records, all on the PMA pathway, with decision counts of two approvals and one 30-day notice. The smaller record sample of three entries shows the same split of two approvals and one 30-day notice. These figures describe the supplied filings as of the snapshot date and are not measures of total company portfolio, sales, or safety performance. [1][2][3]
The FDA database pages for P100044 and its supplements carry a standing note that a supplement may have changed the device description, function, or indication from the original approval, directing readers to the supplements for current information. The page for P100044 lists S061 among its supplements and shows a last-updated date of October 26, 2026. [6]
